Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis
- Authors
- Jang, Won Il; Kim, Mi-Sook; Lim, Jung Sub; Yoo, Hyung Jun; Seo, Young Seok; Han, Chul Ju; Park, Su Cheol; Kay, Chul Seung; Kim, Myungsoo; Jang, Hong Seok; Lee, Dong Soo; Chang, Ah Ram; Park, Hae Jin
- Issue Date
- Sep-2015
- Publisher
- International Institute of Anticancer Research
- Keywords
- Hepatocellular carcinoma; metformin; radiotherapy; survival
- Citation
- Anticancer Research, v.35, no.9, pp 5047 - 5054
- Pages
- 8
- Journal Title
- Anticancer Research
- Volume
- 35
- Number
- 9
- Start Page
- 5047
- End Page
- 5054
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10338
- ISSN
- 0250-7005
1791-7530
- Abstract
- Background: The present study aimed to evaluate the effects of metformin on the clinical outcomes of patients receiving radiotherapy for inoperable hepatocellular carcinoma. Patients and Methods: The medical records of 217 patients treated with stereotactic body or hypofractionated radiotherapy for inoperable hepatocellular carcinoma were reviewed. Patients were divided into the metformin group (n = 19) and the non-metformin group (n = 198), including those with diabetes (n = 29), and those without (n = 169). We performed a propensity score-matching analysis comparing the two groups. Results: In the propensity score-matched cohort (n = 76), the overall survival rate of the metformin group was higher than that of the non-metformin group (2-year, 76% vs. 37%, p = 0.022). The adjusted Cox proportional hazards model revealed that metformin usage was a significant factor for mortality (adjusted hazard ratio = 0.361; 95% confidence interval = 0.139-0.935). Conclusion: The use of metformin in patients with hepatocellular carcinoma receiving radiotherapy was associated with higher overall survival.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Radiation Oncology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.